Helsinn appoints Dr Melanie Rolli as Group Chief Operating Officer
19. Mai 2022 08:30 ET
|
Helsinn Healthcare S.A.
Helsinn appoints Dr Melanie Rolli as Group Chief Operating Officer Lugano, Switzerland, May 19, 2022 – Helsinn Group, a fully integrated, global biopharma company with a diversified pipeline of...
Helsinn to present data at upcoming AMMF’s 2022 European Cholangiocarcinoma Conference
11. Mai 2022 07:00 ET
|
Helsinn Healthcare S.A.
Helsinn to present data at upcoming AMMF’s 2022 European Cholangiocarcinoma Conference Lugano, Switzerland, May 11, 2022 - Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with...
Juniper Biologics signs exclusive license agreement with Helsinn for infigratinib (INN) for the emerging markets
04. Mai 2022 02:00 ET
|
Helsinn Healthcare S.A.
Juniper Biologics signs exclusive license agreement with Helsinn for infigratinib (INN) for the emerging markets* Lugano, Switzerland, and Singapore, 04 May 2022 – Juniper Biologics Pte Ltd , a...
Taiho Pharmaceutical Obtains Approval to Manufacture and Market NK1 Receptor Antagonist Arokaris® I.V. Infusion 235mg in Japan
28. März 2022 04:15 ET
|
Helsinn Healthcare S.A.
Taiho Pharmaceutical Obtains Approval to Manufacture and Market NK1 Receptor Antagonist Arokaris® I.V. Infusion 235mg in Japan Tokyo, Japan, and Lugano, Switzerland March 28, 2022 - Taiho...
Helsinn Group and BridgeBio Pharma Announce Update to Strategic Collaboration to Develop, Manufacture and Commercialize Infigratinib in Oncology Indications in the U.S.
03. März 2022 07:30 ET
|
Helsinn Healthcare S.A.
Helsinn Group and BridgeBio Pharma Announce Update to Strategic Collaboration to Develop, Manufacture and Commercialize Infigratinib in Oncology Indications in the U.S. Helsinn gains an exclusive...
Verity Pharmaceuticals™ and Helsinn Therapeutics sign exclusive agreement for the promotion of Akynzeo® and Valchlor® in Puerto Rico
16. Februar 2022 07:00 ET
|
Helsinn Healthcare S.A.
Verity Pharmaceuticals™ and Helsinn Therapeutics sign exclusive agreement for the promotion of Akynzeo® and Valchlor® in Puerto Rico Toronto, Ontario and Lugano, Switzerland, February 16, 2022 ...
AnaCardio exercises option to license a program in heart failure from Helsinn
03. Februar 2022 10:32 ET
|
Helsinn Healthcare S.A.
AnaCardio exercises option to license a program in heart failure from Helsinn Lugano, Switzerland and Stockholm, Sweden, February 3, 2022 - Helsinn Group (“Helsinn”), a fully integrated, global...
Helsinn Launches Fully Integrated Targeted Therapy (FITT) Strategy and Announces Leadership and Structural Changes
13. Januar 2022 07:00 ET
|
Helsinn Healthcare S.A.
Helsinn Launches Fully Integrated Targeted Therapy (FITT) Strategy and Announces Leadership and Structural Changes Strategy focuses on developing and commercializing a differentiated pipeline of...
Helsinn Group Announces European Medicines Agency’s (EMA) Acceptance for review of the Marketing Authorization Application (MAA) for Infigratinib for Patients with Cholangiocarcinoma with Fibroblast Growth Factor Receptor 2 Fusions or Rearr
21. Dezember 2021 05:00 ET
|
Helsinn Healthcare S.A.
Helsinn Group Announces European Medicines Agency’s (EMA) Acceptance for review of the Marketing Authorization Application (MAA) for Infigratinib for Patients with Cholangiocarcinoma with Fibroblast...
Helsinn and Xediton sign exclusive license and distribution agreement for TRUSELTIQ™ (infigratinib) in Canada
20. Dezember 2021 08:03 ET
|
Helsinn Healthcare S.A.
Helsinn and Xediton sign exclusive license and distribution agreement for TRUSELTIQ™ (infigratinib) in Canada Lugano, Switzerland, and Mississauga, Ontario, 20 December 2021 – Helsinn Group...